Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK

N/AEnrolling By InvitationNCT04145401

MicroPort Orthopedics Inc.45 enrolled

Overview

Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its EVOLUTION® Revision CCK Tibia and EVOLUTION® Revision CCK Femur with EVOLUTION® CCK Tibial inserts. These type of studies are required by regulatory authorities for all devices that have been approved in Europe (EU) to evaluate the medium and long term clinical evidence. This study has been designed in accordance with MEDDEV2.12/2 rev 2 (European Medical Device Vigilance System) and ISO (International Organization for Standardization) 14155:2011 guidelines.

The objectives of this study are: 1. To estimate the individual component survivorship of EVOLUTION® Revision Tibia, EVOLUTION® Revision CCK Femur, and EVOLUTION® CCK Tibial Insert. 2. To find out the cumulative incidence of component revision of each component in this combination. 3. To find out the functional outcome scores at early, midterm, and long-term follow-up.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Knee Osteoarthritis

Interventions

Revision Knee implantsDEVICE

Primary knee arthroplasty or a revision knee that requires a revision procedure.

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires the study (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert) 2. Decision to perform the study index surgery with the required study components (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert) is pre-determined regardless of the research. 3. Previously implanted subjects must be enrolled within 3 years (+6 months) of their study index surgery 4. Willing and able to complete required study visits and assessments through the 10 year post-operative follow-up visit. Bilateral subjects can have both TKAs enrolled in the study provided: 1. the specified combination of components (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert) were implanted in both 2. all other aspects of the Inclusion/Exclusion Criteria are satisfied 3. enrollment does not exceed the subject count specified 4. the subject agrees to a second Informed Consent document and data collection specific to the second TKA. Exclusion Criteria: 1. Skeletally immature (less than 21 years of age) at time of implantation. 2. Has an overt infection at the time of implantation. 3. Has inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable. 4. Currently enrolled in another clinical investigation which would affect the endpoints of this protocol. 5. Has documented substance abuse issues. 6. Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study. 7. Currently incarcerated or has impending incarceration. 8. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol.

Locations (1)

HCA Research Institute, OrthoONE at Swedish Medical Center

Englewood, Colorado, United States

Outcomes

Primary Outcomes

Individual component survivorship

Individual component survivorship for tibial base, femoral, and tibial insert at specified intervals out to 10 years follow-up.